Organogenesis Holdings Inc. (ORGO) stock
ORGONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.85+0.04 (+5.13%)
Close on Nov 18, 2026Market cap $109.79MP/E –Yield –
Organogenesis operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Organogenesis's operating income for the twelve months ending Jun 30, 2026 was -$35.87M. For fiscal 2025 it was $44.69M. The highest annual figure on record is $72.22M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.69M | – |
| FY2024 | Dec 31, 2024 | -$1.28M | -110.2% |
| FY2023 | Dec 31, 2023 | $12.53M | -43.8% |
| FY2022 | Dec 31, 2022 | $22.30M | -69.1% |
| FY2021 | Dec 31, 2021 | $72.22M | +170.5% |
| FY2020 | Dec 31, 2020 | $26.70M | – |
| FY2019 | Dec 31, 2019 | -$29.85M | – |
| FY2018 | Dec 31, 2018 | -$51.56M | – |
| FY2017 | Dec 31, 2017 | -$5.49M | – |
| FY2016 | Dec 31, 2016 | -$8.78M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$50.99M | – |
| Q1 FY2026 | Mar 31, 2026 | -$68.89M | – |
| Q4 FY2025 | Dec 31, 2025 | $63.29M | +519.3% |
| Q3 FY2025 | Sep 30, 2025 | $20.73M | +232.1% |
| Q2 FY2025 | Jun 30, 2025 | -$12.58M | – |
| Q1 FY2025 | Mar 31, 2025 | -$26.75M | – |
| Q4 FY2024 | Dec 31, 2024 | $10.22M | – |
| Q3 FY2024 | Sep 30, 2024 | $6.24M | -22.5% |
| Q2 FY2024 | Jun 30, 2024 | -$13.89M | -242.6% |
| Q1 FY2024 | Mar 31, 2024 | -$3.85M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.27M | -114.6% |
| Q3 FY2023 | Sep 30, 2023 | $8.05M | +352.5% |
| Q2 FY2023 | Jun 30, 2023 | $9.75M | -18.3% |
| Q1 FY2023 | Mar 31, 2023 | -$4.00M | – |
| Q4 FY2022 | Dec 31, 2022 | $8.72M | -55.9% |
| Q3 FY2022 | Sep 30, 2022 | $1.78M | -89.1% |
| Q2 FY2022 | Jun 30, 2022 | $11.94M | -49.4% |
| Q1 FY2022 | Mar 31, 2022 | -$128.00K | -101.0% |
| Q4 FY2021 | Dec 31, 2021 | $19.75M | -8.5% |
| Q3 FY2021 | Sep 30, 2021 | $16.26M | -28.7% |
| Q2 FY2021 | Jun 30, 2021 | $23.59M | – |
| Q1 FY2021 | Mar 31, 2021 | $12.62M | – |
| Q4 FY2020 | Dec 31, 2020 | $21.59M | – |
| Q3 FY2020 | Sep 30, 2020 | $22.80M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.25M | – |
| Q1 FY2020 | Mar 31, 2020 | -$15.08M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.15M | – |
| Q3 FY2019 | Sep 30, 2019 | -$8.27M | – |
| Q2 FY2019 | Jun 30, 2019 | -$7.32M | – |
| Q1 FY2019 | Mar 31, 2019 | -$12.12M | – |
| Q4 FY2018 | Dec 31, 2018 | -$4.48M | – |
| Q3 FY2018 | Sep 30, 2018 | -$10.07M | – |
| Q2 FY2018 | Jun 30, 2018 | -$17.03M | -782.4% |
| Q1 FY2018 | Mar 31, 2018 | -$19.98M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.40M | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.62M | – |
| Q2 FY2017 | Jun 30, 2017 | $2.50M | – |
| Q1 FY2017 | Mar 31, 2017 | -$2.97M | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.30M | – |
| Q3 FY2016 | Sep 30, 2016 | -$14.49K | – |
See a number that looks wrong?